EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Pharmacomicrobiomics of Non-Antibiotic Drugs: Mechanisms and Clinical Consequences of Gut Microbiota Alterations

Caterina Nela Dumitru, Alina Oana Dumitru iD, Larisa Goroftei, Elena Niculet iD, Mariana Daniela Ignat, Liliana Baroiu iD, Aurel Nechita, Gabriela Balan iD

Pharmaceutics · 26.05.2026 · 18 (6) · 651

DOI: 10.3390/pharmaceutics18060651 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Pharmaceutics, online erschienen am 26.05.2026. Verfasst von Caterina Nela Dumitru und 7 weiteren Autor:innen. Beteiligte Einrichtung: Research Centre in the Medical-Pharmaceutical Field, Faculty of Medicine and Pharmacy, "Dunărea de Jos" University of Galați, 35 Al. I. Cuza Street, …. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 121 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: "Dunarea de Jos" University of Galati, “Dunarea de Jos” University of Galati.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The gut microbiota constitutes a metabolically active “second genome” that profoundly modulates drug pharmacokinetics, pharmacodynamics, and adverse reaction profiles. Beyond antibiotics, widely prescribed non-antibiotic pharmacotherapies exert clinically relevant pharmacomicrobiomic effects with implications for therapeutic optimisation and pharmacovigilance.

Methods

This narrative review, conducted following PRISMA 2020 reporting principles (without PROSPERO pre-registration), searched PubMed/MEDLINE, Scopus, Web of Science, and Cochrane Library (January 2015–December 2024) for evidence on proton pump inhibitors (PPIs), metformin, NSAIDs, statins, SGLT2 inhibitors, and oral iron. Evidence tables included clinical human studies with molecular microbiota characterisation (16S rRNA or shotgun metagenomics), ≥20 participants, and a control arm; preclinical data informed mechanistic synthesis.

Results

Of 68 eligible studies, 20 met criteria for the evidence tables. PPIs significantly remodelled gut microbiota composition with enrichment of oral-origin taxa (“oralisation of the gut”), associating with Clostridioides difficile infection and SIBO. Metformin enriched Akkermansia muciniphila and butyrate producers, contributing causally to glycaemic efficacy. NSAIDs compromised barrier integrity, with synergistic dysbiosis under PPI co-prescription. Statins correlated with reduced prevalence of the dysbiotic Bact2 enterotype. SGLT2 inhibitor data remained discordant. Oral iron consistently enriched Enterobacteriaceae at the expense of beneficial commensals.

Schlagwörter

Stichwörter der Autor:innen

clinical pharmacologydeprescribingdrug metabolismdrug-induced dysbiosisdrug–microbiome interactionsgut microbiotametforminoral ironpharmacomicrobiomicspharmacovigilanceproton pump inhibitors

Autor:innen und Institutionen

  • Research Centre in the Medical-Pharmaceutical Field, Faculty of Medicine and Pharmacy, "Dunărea de Jos" University of Galați, 35 Al. I. Cuza Street, 800010 Galați, Romania.
  • "Sf. Cuvioasa Parascheva" Clinical Hospital of Infectious Diseases, 800179 Galați, Romania.
  • Faculty of Medicine and Pharmacy, "Dunărea de Jos" University of Galați, 35 Al. I. Cuza Street, 800010 Galați, Romania.
  • "Sf. Ioan" Clinical Emergency Pediatric Hospital, 800487 Galați, Romania.
  • "Sf. Apostol Andrei" Emergency Clinical Hospital, 800578 Galați, Romania.

ORCID-Profile: Alina Oana Dumitru, Elena Niculet, Liliana Baroiu, Gabriela Balan

Förderung

  • "Dunarea de Jos" University of Galati
  • “Dunarea de Jos” University of Galati

Zitieren

APA

Dumitru, C. N., Dumitru, A. O., Goroftei, L., Niculet, E., Ignat, M. D., Baroiu, L., Nechita, A., & Balan, G. (2026). Pharmacomicrobiomics of Non-Antibiotic Drugs: Mechanisms and Clinical Consequences of Gut Microbiota Alterations. Pharmaceutics, 18(6), 651. https://doi.org/10.3390/pharmaceutics18060651

Vancouver

Dumitru CN, Dumitru AO, Goroftei L, Niculet E, Ignat MD, Baroiu L, et al. Pharmacomicrobiomics of Non-Antibiotic Drugs: Mechanisms and Clinical Consequences of Gut Microbiota Alterations. Pharmaceutics. 2026;18(6):651. doi:10.3390/pharmaceutics18060651

BibTeX
@article{Dumitru2026,
  author = {Dumitru, Caterina Nela and Dumitru, Alina Oana and Goroftei, Larisa and Niculet, Elena and Ignat, Mariana Daniela and Baroiu, Liliana and Nechita, Aurel and Balan, Gabriela},
  title = {Pharmacomicrobiomics of Non-Antibiotic Drugs: Mechanisms and Clinical Consequences of Gut Microbiota Alterations},
  journal = {Pharmaceutics},
  year = {2026},
  volume = {18},
  number = {6},
  pages = {651},
  doi = {10.3390/pharmaceutics18060651}
}
Kostenlos starten →